GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Debt-to-Revenue

Arctic Bioscience AS (OSL:ABS) Debt-to-Revenue : 0.05 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Arctic Bioscience AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Arctic Bioscience AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr1.77 Mil. Arctic Bioscience AS's annualized Revenue for the quarter that ended in Jun. 2024 was kr33.49 Mil. Arctic Bioscience AS's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.05.


Arctic Bioscience AS Debt-to-Revenue Historical Data

The historical data trend for Arctic Bioscience AS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Debt-to-Revenue Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 0.25 0.45 0.06 0.03 0.17

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.03 0.11 0.19 0.05

Competitive Comparison of Arctic Bioscience AS's Debt-to-Revenue

For the Biotechnology subindustry, Arctic Bioscience AS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arctic Bioscience AS's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's Debt-to-Revenue falls into.



Arctic Bioscience AS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Arctic Bioscience AS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.531 + 2.049) / 33.75
=0.17

Arctic Bioscience AS's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.767) / 33.492
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Arctic Bioscience AS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS Business Description

Traded in Other Exchanges
N/A
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand. The company operates in Norway, Europe, Australia and APAC.

Arctic Bioscience AS Headlines

No Headlines